Cargando…
How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia
Venetoclax has transformed the therapeutic landscape of acute myeloid leukemia (AML). Hypomethylating agents with venetoclax (HMA-VEN) have significantly improved outcomes and have become the standard therapy for older/unfit patients with newly diagnosed AML and are comparable to intensive chemother...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785772/ https://www.ncbi.nlm.nih.gov/pubmed/35072368 http://dx.doi.org/10.1097/PPO.0000000000000567 |